287 related articles for article (PubMed ID: 29349597)
1. Drug repurposing screening identifies bortezomib and panobinostat as drugs targeting cancer associated fibroblasts (CAFs) by synergistic induction of apoptosis.
Lee HM; Lee E; Yeo SY; Shin S; Park HK; Nam DH; Kim SH
Invest New Drugs; 2018 Aug; 36(4):545-560. PubMed ID: 29349597
[TBL] [Abstract][Full Text] [Related]
2. Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer.
Yin YP; Shi WH; Deng K; Liu XL; Li H; Lv XT; Lui VWY; Ding C; Hong B; Lin WC
Acta Pharmacol Sin; 2021 Aug; 42(8):1298-1310. PubMed ID: 33139838
[TBL] [Abstract][Full Text] [Related]
3. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
Takai K; Le A; Weaver VM; Werb Z
Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
[TBL] [Abstract][Full Text] [Related]
4. Tumor microenvironment-based screening repurposes drugs targeting cancer stem cells and cancer-associated fibroblasts.
Lee PJ; Ho CC; Ho H; Chen WJ; Lin CH; Lai YH; Juan YC; Chu WC; Lee JH; Su SF; Chen HY; Chen JJW; Chang GC; Li KC; Yang PC; Chen HW
Theranostics; 2021; 11(19):9667-9686. PubMed ID: 34646392
[TBL] [Abstract][Full Text] [Related]
5. Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms.
Yang L; Zhang S; George SK; Teng R; You X; Xu M; Liu H; Sun X; Amin HM; Shi W
Oncotarget; 2015 Jun; 6(17):14953-69. PubMed ID: 25879451
[TBL] [Abstract][Full Text] [Related]
6. Targeting nuclear receptors in cancer-associated fibroblasts as concurrent therapy to inhibit development of chemoresistant tumors.
Chan JSK; Sng MK; Teo ZQ; Chong HC; Twang JS; Tan NS
Oncogene; 2018 Jan; 37(2):160-173. PubMed ID: 28892046
[TBL] [Abstract][Full Text] [Related]
7. Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.
Zhang M; He J; Liu Z; Lu Y; Zheng Y; Li H; Xu J; Liu H; Qian J; Orlowski RZ; Kwak LW; Yi Q; Yang J
Oncotarget; 2015 Apr; 6(11):8567-78. PubMed ID: 25895124
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast activation protein targeted near infrared photoimmunotherapy (NIR PIT) overcomes therapeutic resistance in human esophageal cancer.
Katsube R; Noma K; Ohara T; Nishiwaki N; Kobayashi T; Komoto S; Sato H; Kashima H; Kato T; Kikuchi S; Tazawa H; Kagawa S; Shirakawa Y; Kobayashi H; Fujiwara T
Sci Rep; 2021 Jan; 11(1):1693. PubMed ID: 33462372
[TBL] [Abstract][Full Text] [Related]
9. HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma.
Lee SW; Yeon SK; Kim GW; Lee DH; Jeon YH; Yoo J; Kim SY; Kwon SH
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572814
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib-loaded mixed micelles realize a "three-in-one" effect for enhanced breast cancer treatment.
Liu J; Xu X; Li Y; Xu J; Zhao R; Liu S; Wu J; Zhang L; Zhang B
Biomater Sci; 2023 Jul; 11(14):4890-4906. PubMed ID: 37306225
[TBL] [Abstract][Full Text] [Related]
11. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
[TBL] [Abstract][Full Text] [Related]
12. Repurposed drug screen identifies cardiac glycosides as inhibitors of TGF-β-induced cancer-associated fibroblast differentiation.
Coleman DT; Gray AL; Stephens CA; Scott ML; Cardelli JA
Oncotarget; 2016 May; 7(22):32200-9. PubMed ID: 27058757
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide rewires mantle cell lymphoma response to bortezomib.
Zhao LL; Liu YF; Peng LJ; Fei AM; Cui W; Miao SC; Hermine O; Gressin R; Khochbin S; Chen SJ; Wang J; Mi JQ
Cancer Med; 2015 Nov; 4(11):1754-66. PubMed ID: 26310857
[TBL] [Abstract][Full Text] [Related]
14. Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.
Tsakiri EN; Terpos E; Papanagnou ED; Kastritis E; Brieudes V; Halabalaki M; Bagratuni T; Florea BI; Overkleeft HS; Scorrano L; Skaltsounis AL; Dimopoulos MA; Trougakos IP
Sci Rep; 2017 Dec; 7(1):17802. PubMed ID: 29259189
[TBL] [Abstract][Full Text] [Related]
15. A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer.
Wang XS; Kong DJ; Lin TY; Li XC; Izumiya Y; Ding XZ; Zhang L; Hu XC; Yang JQ; Gao SG; Lam KS; Li YP
Acta Pharmacol Sin; 2017 Jun; 38(6):931-942. PubMed ID: 28552907
[TBL] [Abstract][Full Text] [Related]
16. New screening system using Twist1 promoter activity identifies dihydrorotenone as a potent drug targeting cancer-associated fibroblasts.
Lee E; Yeo SY; Lee KW; Lee JA; Kim KK; Kim SH
Sci Rep; 2020 Apr; 10(1):7058. PubMed ID: 32341496
[TBL] [Abstract][Full Text] [Related]
17. Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment.
Li C; Hu J; Li W; Song G; Shen J
Biomater Sci; 2016 Dec; 5(1):77-88. PubMed ID: 27822577
[TBL] [Abstract][Full Text] [Related]
18. Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors.
Bat-Erdene A; Miki H; Oda A; Nakamura S; Teramachi J; Amachi R; Tenshin H; Hiasa M; Iwasa M; Harada T; Fujii S; Sogabe K; Kagawa K; Yoshida S; Endo I; Aihara K; Abe M
Oncotarget; 2016 Nov; 7(48):79064-79075. PubMed ID: 27738323
[TBL] [Abstract][Full Text] [Related]
19. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
Malek E; Driscoll JJ
Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
[TBL] [Abstract][Full Text] [Related]
20. Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines.
Takahashi K; Inukai T; Imamura T; Yano M; Tomoyasu C; Lucas DM; Nemoto A; Sato H; Huang M; Abe M; Kagami K; Shinohara T; Watanabe A; Somazu S; Oshiro H; Akahane K; Goi K; Kikuchi J; Furukawa Y; Goto H; Minegishi M; Iwamoto S; Sugita K
PLoS One; 2017; 12(12):e0188680. PubMed ID: 29236701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
